glucagon receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-29. Anything still debated is marked as such rather than presented as settled.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
The "Pillar" device is a treatment for snoring and obstructive sleep apnea; it is thin, narrow strips of polyester. Three strips are inserted into the roof of the mouth (the soft palate) using a modified syringe and local anesthetic, in order to stiffen the soft palate. This procedure addresses one of the most common causes of snoring and sleep apnea — vibration or collapse of the soft palate. It was approved by the FDA for snoring in 2002 and for obstructive sleep apnea in 2004. A 2013 meta-analysis found that "the Pillar implant has a moderate effect on snoring and mild-to-moderate obstructive sleep apnea" and that more studies with high level of evidence were needed to arrive at a definite conclusion; it also found that the polyester strips work their way out of the soft palate in about 10% of the people in whom they are implanted.
D-amino-acid dehydrogenase (EC 1.4.99.1, transferred to 1.4.99.6) is a bacterial enzyme that catalyses the oxidation of D-amino acids into their corresponding oxoacids. It contains both flavin and nonheme iron as cofactors. The enzyme has a very broad specificity and can act on most D-amino acids.
Crick was aware that research on consciousness was a difficult task, as he wrote to Martynas Yčas in April 1996:I don't think we shall fully understand consciousness by the end of this century, but it's possible we can get a glimpse of the answer by then. Whether it will all fall into place, as molecular biology did, without a vital force, or whether we need a radical formulation, only time will tell. Best wishes, Yours, Francis. P.S. By the way, I've not been knighted.
Apart from user contributed missions it is also possible to play co-operatively through the original Half-Life game and its expansions, though the expansions can only be accessed if owned by everyone in the server. Team Fortress Classic – Originally a mod ported from Quakeworld that introduced a class-system style of play that allowed for many diverse playing styles. With the introduction of Steam it became a standalone game and as of October 10, 2007 it has a commercially released sequel Team Fortress 2. Trinity Command – Similar to Unreal Tournament's Domination game mode where two teams try to control various points on the map. GameStar said the included bots are useful but noted the maps as monotonous and classes unbalanced. Turbo – A racing game where players control snarks, beetle-like creatures from Half-Life. PC Zone gave it a rating two out of five, calling the mod great fun but noted the lack of players online and its tendency to crash. Underworld: Bloodline – an asymmetric multiplayer FPS based on the Underworld film franchise. Developed by Black Widow Games in 2003 as a promotional tie-in for the film Underworld, it is the only officially licensed Half-Life mod associated with a Hollywood movie. The mod was available on the Sony Pictures official website until the end of 2007. Players choose between Vampires and Lycans, engaging in objective-based combat across urban maps. Each faction has distinct classes, weapons, and movement abilities.
Sources: en.wikipedia.org
In May 1937, they issued parallel reports, one in the Zeitschrift für Physik with Meitner as the principal author, and one in the Chemische Berichte with Hahn as the principal author. Hahn concluded his by stating emphatically: Vor allem steht ihre chemische Verschiedenheit von allen bisher bekannten Elementen außerhalb jeder Diskussion ("Above all, their chemical distinction from all previously known elements needs no further discussion"). Meitner, however, was increasingly uncertain. She considered the possibility that the reactions were from different isotopes of uranium; three were known: uranium-238, uranium-235 and uranium-234. However, when she calculated the neutron cross section, it was too large to be anything other than the most abundant isotope, uranium-238. She concluded that it must be another case of the nuclear isomerism that Hahn had discovered in protactinium. She therefore ended her report on a very different note to Hahn, reporting that: Also müssen die Prozesse Einfangprozesse des Uran 238 sein, was zu drei isomeren Kernen Uran 239 führt. Dieses Ergebnis ist mit den bisherigen Kernvorstellungen sehr schwer in Übereinstimmung zu bringen ("The processes must be neutron capture by uranium-238, which leads to three isomeric nuclei of uranium-239. This result is very difficult to reconcile with current concepts of the nucleus.") With the Anschluss, Germany's annexation of Austria on 12 March 1938, Meitner lost her Austrian citizenship, and fled to Sweden.
A systemic disease is one that affects a number of organs and tissues, or affects the body as a whole. It differs from a localized disease, which is a disease affecting only part of the body (e.g., a mouth ulcer).
Biodistribution of 14C-labelled docetaxel in three patients showed the bulk of the drug to be metabolised and excreted in bile to the faeces. Of the radioactively labelled docetaxel administered, 80% was eliminated to the faeces with 5% in the urine over seven days, an indication that urinary excretion of docetaxel is minimal. Saliva contributed minimal excretion and no excretion was detected through pulmonary means. The terminal half-life of docetaxel was determined as approximately 86 hours, through prolonged plasma sampling, contrary to the clinically stated terminal half-life of 10–18 hours.
=== Arts critics === Gustav Kobbé (1877), opera scholar and music critic of the New York Herald Clifton Fadiman (1925), book critic for The New Yorker and judge for the Book of the Month Club Edward Downes (1933), music critic, former host on the Metropolitan Opera radio broadcasts, son of music critic Olin Downes Ralph J.
Plate cells of choice in growth medium into a live cell imaging dish or chamber slide. It is important to ensure that a monolayer is formed as clumps will provide inaccurate results due to an uneven cell density. Titrating the cells to determine the optimal plating density is necessary. When the confluency of the cells are ideal, use a pipette tip to scratch a wound through the entire center of the well. As mentioned previously, this is where the potential inconsistency comes into play with this assay. If the scratch is made manually, it is important to make sure that the wound is visible on both side of the field of view and should be around 0.5 mm wide. The cells can then be placed on a microscope with a relative objective of 20x. Begin time-lapse microscopy and adjust the parameters according to the variety of cells studying. Fast-growing cells may require shorter time intervals to acquire more accurate cell speed.
Sources: en.wikipedia.org
== Indications for use == Abciximab is indicated for use in individuals undergoing percutaneous coronary intervention (angioplasty with or without stent placement). The use of abciximab in this setting is associated with a decreased incidence of ischemic complications due to the procedure and a decreased need for repeated coronary artery revascularization in the first month following the procedure. Research also shows that this drug can be of use for patients with diabetes and chronic kidney disease. It is not the appropriate drug of choice if a patient is scheduled for an emergency surgery (i.e., heart surgery) because bleeding time may take about 12 hours to normalize. Pediatric uses include treatment of Kawasaki disease.
Low-velocity: Less than 335 m/s (1,100 ft/s) Low velocity wounds are typical of small caliber handguns. They do not usually cause extensive soft tissue damage, and in the Gustilo open fracture classification are classified as Type 1 or 2 wounds.
== Etymology and regional names == The name "bilberry" appears to have a Scandinavian origin, possibly from as early as 1577, while the earliest known English use of the name "blueberry" dates back to 1594, appearing in the Acts of Parliament of Scotland. The name "bilberry" is similar to the Danish word bølle for whortleberry with the addition of "berry". In Scandinavian languages, terms for bilberries have names with the meaning "blueberry", such as blåbär in Swedish and blåbær in Danish and Norwegian. The bilberry (especially Vaccinium myrtillus) may be called blaeberry in Scottish and Northern English regional dialects, whortleberry in southern England, and fraochán in Ireland.
== Further reading == Selassie CD (2003). "History of Quantitative Structure-Activity Relationships" (PDF). In Abraham DJ (ed.). Burger's medicinal Chemistry and Drug Discovery. Vol. 1 (6th ed.). New York: Wiley. pp. 1–48. ISBN 978-0-471-27401-8. Shityakov S, Puskás I, Roewer N, Förster C, Broscheit J (2014). "Three-dimensional quantitative structure-activity relationship and docking studies in a series of anthocyanin derivatives as cytochrome P450 3A4 inhibitors". Advances and Applications in Bioinformatics and Chemistry. 7: 11–21. doi:10.2147/AABC.S56478. PMC 3970920. PMID 24741320.
=== 17 March === The United Nations said the RSF detained more than 60 peacekeepers, abducted eight civilian staff, and seized eight vehicles and 280,000 litres of fuel from a United Nations Interim Security Force for Abyei (UNISFA) logistics convoy heading from a refueling mission in Kadugli.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.